Deanna Teoh1, Gretchen Hultman2, McKenzie DeKam3, Rachel Isaksson Vogel1,4, Levi S Downs1, Melissa A Geller1, Chap Le5, Genevieve Melton2,6, Shalini Kulasingam7. 1. Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN. 2. Institute for Health Informatics, University of Minnesota, Minneapolis, MN. 3. Medical School, University of Minnesota, Minneapolis, MN. 4. Biostatistics & Bioinformatics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN. 5. School of Public Health, Division of Biostatistics, University of Minnesota, Minneapolis, MN. 6. Department of Surgery, Division of Colon & Rectal Surgery, University of Minnesota, Minneapolis, MN. 7. Department of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN.
Abstract
OBJECTIVE: The aim of the study was to estimate the excess cost of guideline nonadherent cervical cancer screening in women beyond the recommended screening ages or posthysterectomy in a single healthcare system. MATERIALS AND METHODS: All Pap tests performed between September 1, 2012, and August 31, 2014, in women younger than 21 years, older than 65 years, or after hysterectomy, were coded as guideline adherent or nonadherent per the 2012 America Society of Colposcopy and Clinical Pathology guidelines. We assumed management of abnormal results per the 2013 America Society of Colposcopy and Clinical Pathology management guidelines. Costs were obtained from a literature review and Center for Medicare and Medicaid Services data and applied to nonadherent screening and subsequent diagnostic tests. RESULTS: During this period, 1,398 guideline nonadherent Pap tests were performed (257 in women <21 years, 536 in women >65 years, and 605 after hysterectomy), with 88 abnormal results: 35 (13.5%) in women younger than 21 years, 14 (2.6%) in women older than 65 years, and 39 (6.5%) in women after hysterectomy. The excess cost for initial screening, diagnostic tests, and follow-up was US $35,337 for 2 years in women younger than 21 years, US $54,378 for 5 years in women older than 65 years, and US $77,340 for 5 years in women after hysterectomy, resulting in a total excess cost of US $166,100 for 5 years. Of the 1,398 women who underwent guideline nonadherent screening, there were only 2 (0.1%) diagnoses of high-grade dysplasia (VaIN3). CONCLUSIONS: Guideline nonadherent cervical cancer screening in women beyond the recommended screening ages and posthysterectomy resulted in costs exceeding US $160,000 for screening, diagnostic tests, and follow-up with minimal improvement in detection of high-grade dysplasia.
OBJECTIVE: The aim of the study was to estimate the excess cost of guideline nonadherent cervical cancer screening in women beyond the recommended screening ages or posthysterectomy in a single healthcare system. MATERIALS AND METHODS: All Pap tests performed between September 1, 2012, and August 31, 2014, in women younger than 21 years, older than 65 years, or after hysterectomy, were coded as guideline adherent or nonadherent per the 2012 America Society of Colposcopy and Clinical Pathology guidelines. We assumed management of abnormal results per the 2013 America Society of Colposcopy and Clinical Pathology management guidelines. Costs were obtained from a literature review and Center for Medicare and Medicaid Services data and applied to nonadherent screening and subsequent diagnostic tests. RESULTS: During this period, 1,398 guideline nonadherent Pap tests were performed (257 in women <21 years, 536 in women >65 years, and 605 after hysterectomy), with 88 abnormal results: 35 (13.5%) in women younger than 21 years, 14 (2.6%) in women older than 65 years, and 39 (6.5%) in women after hysterectomy. The excess cost for initial screening, diagnostic tests, and follow-up was US $35,337 for 2 years in women younger than 21 years, US $54,378 for 5 years in women older than 65 years, and US $77,340 for 5 years in women after hysterectomy, resulting in a total excess cost of US $166,100 for 5 years. Of the 1,398 women who underwent guideline nonadherent screening, there were only 2 (0.1%) diagnoses of high-grade dysplasia (VaIN3). CONCLUSIONS: Guideline nonadherent cervical cancer screening in women beyond the recommended screening ages and posthysterectomy resulted in costs exceeding US $160,000 for screening, diagnostic tests, and follow-up with minimal improvement in detection of high-grade dysplasia.
Authors: Dik Habbema; Sheila Weinmann; Marc Arbyn; Aruna Kamineni; Andrew E Williams; Inge M C M de Kok; Folkert van Kemenade; Terry S Field; Joost van Rosmalen; Martin L Brown Journal: Int J Cancer Date: 2017-03-01 Impact factor: 7.396
Authors: Mélanie Drolet; Marc Brisson; Elizabeth Maunsell; Eduardo L Franco; François Coutlée; Alex Ferenczy; William Fisher; James A Mansi Journal: Psychooncology Date: 2011-06-21 Impact factor: 3.894
Authors: Deanna G K Teoh; Amity E Marriott; Rachel Isaksson Vogel; Ryan T Marriott; Charles W Lais; Levi S Downs; Shalini L Kulasingam Journal: Am J Obstet Gynecol Date: 2014-06-30 Impact factor: 8.661
Authors: Deanna Kepka; Nancy Breen; Jessica B King; Helen I Meissner; Katherine B Roland; Vicki B Benard; Mona Saraiya Journal: Am J Prev Med Date: 2014-08-27 Impact factor: 5.043
Authors: Jane J Kim; Nicole G Campos; Stephen Sy; Emily A Burger; Jack Cuzick; Philip E Castle; William C Hunt; Alan Waxman; Cosette M Wheeler Journal: Ann Intern Med Date: 2015-09-29 Impact factor: 25.391
Authors: Mary O'Keeffe; Adrian C Traeger; Tammy Hoffmann; Giovanni Esteves Ferreira; Jason Soon; Christopher Maher Journal: BMJ Open Date: 2019-06-24 Impact factor: 2.692
Authors: Hillary Hosier; Sangini S Sheth; Carlos R Oliveira; Lauren E Perley; Alla Vash-Margita Journal: Am J Obstet Gynecol Date: 2021-07-10 Impact factor: 8.661